Information Provided By: 
Fly News Breaks for December 31, 2019
BTAI
Dec 31, 2019 | 13:26 EDT
Canaccord analyst Sumant Kulkarni raised his price target for BioXcel Therapeutics to $27 from $24 after the company announced that it is initiating its SERENITY Phase 3 pivotal program for its lead asset, BXCL501. The analyst, who questions if BioXcel could be the "next under-followed CNS stock with the potential for a big move," keeps a Buy rating on the shares.
News For BTAI From the Last 2 Days
There are no results for your query BTAI
